Zelluna Immunotherapy Receives Investment from Takeda Ventures

Zelluna Immunotherapy, an Oslo, Norway-based company focused on allogeneic “off the shelf” T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer, received an investment from Takeda Ventures, the strategic investing arm of Takeda.

The deal’s amount was not disclosed.

The company intends to use the funds to enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and continue the advancement of its platform with additional programs reaching the preclinical stage.

Zelluna Immunotherapy, headed by Namir Hazan, CEO, is a pioneer in the development and application of allogeneic T cells receptor (TCR), guided natural killer (NK), cell immunotherapies for solid cancers. The company is currently developing a portfolio TCRs that target tumors to guide NK cell responses. This will allow them to induce cancer responses that are safe and efficient, but also last a long time.

TCR-NK products, a new class of allogeneic cell therapies, combine the inherent, pancancer killing mechanism, efficiency and allogeneic nature NK cells with TCRs to target specific cancers. TCRs can be used to arm NK cells, potentially allowing for the treatment of a wide variety of cancers.



Leave a Comment